{
  "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "docSlug": "5062b9a9257606648ea145bccd66e04d",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 41,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "solution",
  "function": "illustrate_case",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "Uses a 'case study' framework to validate the proposed strategy by drawing a parallel to an existing successful drug (Osimertinib).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/10",
  "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "deckJsonHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json",
  "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.34,
        "x": 0.06,
        "y": 0.543
      },
      "kind": "callout",
      "text": "CASE STUDY Osimertinib for EGFR+ NSCLC",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e163c75-01bc-4a80-bb6b-ebce719c8a97",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.33,
        "x": 0.63,
        "y": 0.543
      },
      "kind": "chart",
      "text": "Significant 1L mPFS improvement & Movement up the treatment paradigm",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "93012432-3cd9-47bb-903e-b48a2781a8c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.71,
        "x": 0.145,
        "y": 0.215
      },
      "kind": "diagram",
      "text": "Selective inhibition of the oncogenic driver + Overcoming treatment-emergent resistance mutations + Treating & preventing brain metastases + Avoiding treatment-limiting adverse events",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce473f79-8825-4310-8d80-8a0945b1190a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.832,
        "x": 0.084,
        "y": 0.464
      },
      "kind": "paragraph",
      "text": "Comparable resistance mutation rates after 1L TKI: ~50% ALK single mutation & ~40% ROS1 G2032R vs. ~50% EGFR T790M",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11b81708-b466-4061-9240-9ebacf2e6d26",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.54,
        "x": 0.06,
        "y": 0.885
      },
      "kind": "source-note",
      "text": "Sources: [1] Dagogo-Jack I. et al., Clin Cancer Res 2019; [2] Gainor J. et al. Cancer Discov. 2016; [4] Gainor J.F. et al., JCO Precision Oncol. 2017; [4] Ohashi K. et al., JCO 2013; [5] Osimertinib FDA package insert.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d69fa9e-1e70-4f29-b524-c05e0a4e9daf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.586,
        "x": 0.207,
        "y": 0.155
      },
      "kind": "title",
      "text": "Potential best-in-class ALK & ROS1 TKIs to overcome the combined medical needs of:",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf7e99a3-ab33-48ed-acbd-7a119417b43a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.038,
        "w": 0.504,
        "x": 0.248,
        "y": 0.065
      },
      "kind": "title",
      "text": "Nuvalent ALK+ and ROS1+ NSCLC Strategy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "256f2e57-9ba9-48e0-9d06-1f44d43cfa5a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "argument-from-analogy",
      "slug": null,
      "matchId": "361c6a7f-ba77-4c14-bebc-18af94dfe6dd",
      "evidence": "Uses Osimertinib case study to justify the strategy for ALK/ROS1",
      "confidence": 0.95
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 10,
      "beatId": "27328397-5fb0-424b-acf4-4be675fda1d4",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents Nuvalent's solution, including their innovative approach to cancer therapy and promising clinical trial results.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "7394c275-2e8b-4ce7-ac85-c375b43f1f48",
      "evidence": "The document highlights the limitations of current therapies and the potential benefits of Nuvalent's solutions.",
      "position": 0,
      "objective": "What are the consequences of not addressing the limitations of current cancer therapies?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}